Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD38 | P28907 | 12/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20958060 | 0.85 | CD38 (0.41) | CD38HTTCYP2D6CYP2B6CYP2C19 | |
| SCHEMBL20564951 | 0.85 | CD38 (0.40) | CD38LMNANPSR1CYP2D6CYP2B6 | |
| SCHEMBL20563854 | 0.85 | CD38 (0.38) | CD38MAPTLMNAHTTALDH1A1 | |
| SCHEMBL20958059 | 0.81 | NOTUM (0.48) | MAPTLMNAHTTALDH1A1TP53 | |
| SCHEMBL20565316 | 0.78 | ALDH1A1 (0.37) | CD38ALDH1A1CYP2D6TP53CYP2C19 | |
| SCHEMBL20958012 | 0.77 | FKBP1A (0.44) | CD38MAPTHTTALDH1A1NPSR1 | |
| SCHEMBL20957951 | 0.76 | CYP3A4 (0.46) | CD38MAPTHTTNPSR1CYP2D6 | |
| SCHEMBL20564999 | 0.76 | TSHR (0.39) | CD38LMNAHTTALDH1A1NPSR1 | |
| SCHEMBL20957980 | 0.75 | CYP1A2 (0.47) | CD38HTTALDH1A1CYP2D6TP53 | |
| SCHEMBL20958063 | 0.75 | TSHR (0.42) | LMNAHTTALDH1A1NPSR1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190135793-A1 | HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135793-A1 | HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE | KDM5A, KDM5B, KDM5C | CD38 791/4885GFER 3584/4885MAPT 3284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.